Rhegmatogenous Retinal Detachment
Conditions
Brief summary
Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients; to prove the percentage of PVR-IC decides the risk of serious PVR occurring after surgery; to investigate the safety and efficacy of early local steroids drug intervention in patients with severe postoperative PVR.
Interventions
DIAGNOSTIC_TESTRPE cell collection and single cell heterogeneity study
Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
PROCEDUREPostoperative intervention
Early local steroids drug intervention in patients with severe postoperative PVR
PROCEDUREConventional Surgery for Retinal Detachment
Conventional Surgery for Retinal Detachment
Sponsors
Shanghai 10th People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* (1) Age: 18-60 years old, regardless of gender; (2) Clinical diagnosis of with rhegmatogenic retinal detachment (RRD); (3) Surgery for Retinal Detachment is required; (4) Myopia \< = 800 degrees; (4) PVR classification: no restrictions; (5) Patients undergoing the first or second operation. (6) Patients volunteered to participate in this study and signed informed consent.
Exclusion criteria
* (1) Exudative detachment of retina; (2) Those who are allergic to the drugs used in the study; (3) Combined with other eye diseases: other fundus diseases, glaucoma, corneal opacity diseases, genetic diseases); (4) history of internal eye surgery \>=3 times; (5) Postoperative follow-up could not be scheduled; (6) Patients with systemic diseases (such as asthma, heart failure, myocardial infarction, liver failure, kidney failure and other major diseases).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular pressure (IOP) | 3 months post operation | Patients' IOP(mmHg) assessed by noncontact tonometer |
| Best Corrected visual Acuity (BCVA） | 3 months post operation | Patients' best corrected visual acuity assessed by logarithmic visual acuity(0.5-1.0； For example, normal vision was 1.0) |
| Retina reattachment rate | 3 months post operation | Percentage of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed retinal detachment band height was 0mm, OCT showed subretinal fluid height was 0um) |
| Number of Severe PVR | 3 months post operation | Number of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed proliferative band height exceeded 0mm, OCT showed proliferative band exceeded 0um) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraocular pressure (IOP) | 12 months post operation | Patients' IOP(mmHg) assessed by noncontact tonometer |
| Retina reattachment rate | 12 months post operation | Percentage of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed retinal detachment band height was 0mm, OCT showed subretinal fluid height was 0um) |
| Number of Severe PVR | 12 months post operation | Number of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed proliferative band height exceeded 0mm, OCT showed proliferative band exceeded 0um) |
| Best Corrected visual Acuity (BCVA） | 12 months post operation | Patients' best corrected visual acuity assessed by logarithmic visual acuity(0.5-1.0； For example, normal vision was 1.0) |
Other
| Measure | Time frame | Description |
|---|---|---|
| RD treatment group1and RD treatment group2 | 1 weeks post operation,3 months post operation,12 months post operation | Proportion (%)of PVR-IC subtypes in RPE cells assessed by 10×Genomics single cell sequencing |
| RD treatment group2 | 2 weeks post operation,3 months post operation,12 months post operation | Patients' IOP (mmHg)assessed by noncontact tonometer; len's opacity(Grade1-4) assessed by PENTACAM; number of participants who occurred subconjunctival chemosis and hemorrhage(area 1/4-1) |
Contacts
Primary ContactFang Wang, MD,phD
Backup ContactConghui Zhang, MD,phD
Outcome results
None listed